Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $23.00 target price on the stock.

A number of other analysts also recently issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Finally, Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday, March 24th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $22.20.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $2.17 on Tuesday. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $72.04 million, a PE ratio of -0.69 and a beta of 1.52. The firm’s 50 day simple moving average is $3.40 and its 200 day simple moving average is $6.02.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, analysts expect that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its stake in Lexeo Therapeutics by 107.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after purchasing an additional 33,013 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after acquiring an additional 7,803 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Lexeo Therapeutics during the 3rd quarter worth approximately $274,000. Finally, Point72 Asset Management L.P. purchased a new position in Lexeo Therapeutics in the 3rd quarter worth approximately $3,348,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.